SEARCH:   Advanced

Blood, 1 November 2007, Vol. 110, No. 9, pp. 3345-3351. Prepublished online as a Blood First Edition Paper on July 18, 2007; DOI 10.1182/blood-2007-02-075036. This Article Full Text (PDF) Supplemental Table All Versions of this Article: blood-2007-02-075036v1 110/9/3345    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rodriguez-Antona, C. Articles by Martinez-Delgado, B. Search for Related Content PubMed PubMed Citation Articles by Rodriguez-Antona, C. Articles by Martinez-Delgado, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 20, 2007 Accepted July 5, 2007 Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas Cristina Rodriguez-Antona, Susanna Leskela, Magdalena Zajac, Marta Cuadros, Javier Alves, Maria Victoria Moneo, Carmen Martin, Juan Cruz Cigudosa, Amancio Carnero, Mercedes Robledo, Javier Benitez, and Beatriz Martinez-Delgado* Hereditary Endocrine Cancer Group, Spanish National Cancer Center (CNIO), Madrid Human Genetics Group, Spanish National Cancer Center (CNIO), Madrid Department of Pathology, Hospital La Paz, Madrid Assay Development Group, Spanish National Cancer Center (CNIO), Madrid Molecular Cytogenetics Group, Spanish National Cancer Center (CNIO), Madrid * Corresponding author; email: bmartinez{at}cnio.es. Peripheral T-cell lymphomas (PTCL) are aggressive tumors in which the current therapy based on multiagent chemotherapy is not successful. Since cytocrome P450 3A subfamily (CYP3A) enzymes are involved in the inactivation of chemotherapy drugs, we hypothesized that CYP3A and P-glycoprotein (MDR1) expression in these lymphomas, could result in a poor clinical response. We measured tumoral CYP3A and MDR1 mRNA content in 44 T-cell lymphomas finding a large variation in CYP3A expression. Multiplex PCR-Analysis and FISH analysis showed genomic gains affecting CYP3A and MDR1 genes in T-cell lines and primary tumors, suggesting that this could be the mechanism underlying the tumoral expression variation. To test whether the tumoral expression of CYP3A and/ or MDR1 could influence PTCL treatment outcome, their expression levels were compared with the clinical response and survival of the patients, finding that a high tumoral expression of CYP3A4 was significantly associated with a lower complete remission rate. This was further investigated with cell lines stably expressing CYP3A4 which exhibited an increased resistance to doxorubicin and etoposide. In conclusion, a high CYP3A4 tumoral expression could be useful to predict poor response to the standard PTCL chemotherapy, in these cases alternative chemotherapy combinations or doses should be explored. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies J. Clin. Pathol., November 1, 2008; 61(11): 1160 - 1167. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020